A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis
Status:
Completed
Trial end date:
2019-07-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how well LY3316531 is tolerated and what side
effects may occur in healthy participants and participants with psoriasis. The study drug
will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into
a vein in the arm).
This is a three-part study. Participants will enroll in only one part. Parts A and B are for
healthy participants and Part C is for participants with psoriasis. Participation could last
between 16 and 57 weeks.